Prognostic significance of IL-8-STAT-3 pathway in astrocytomas: Correlation with IL-6, VEGF and microvessel morphometry

Cytokine

Volumn 55, Issue 3, 2011, Pages 387-395

  Piperi, Christina ^a   Samaras, Vassilis ^a   Levidou, Georgia ^a   Kavantzas, Nikolaos ^a   Boviatsis, Efstathios ^a   Petraki, Kalliopi ^b   Grivas, Athanasios ^b   Barbatis, Calypso ^c   Varsos, Vassilis ^c   Patsouris, Efstratios ^a   Korkolopoulou, Penelope ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b METROPOLITAN HOSPITAL   (Greece)

^c RED CROSS HOSPITAL   (Greece)

Author keywords

Astrocytoma; IL 6; IL 8; STAT 3; VEGF

Indexed keywords

INTERLEUKIN 6; INTERLEUKIN 8; STAT3 PROTEIN; VASCULOTROPIN;

ADULT; AGED; ARTICLE; ASTROCYTOMA; CANCER GRADING; CANCER GROWTH; CANCER SURVIVAL; CELL INFILTRATION; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; FEMALE; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MAJOR CLINICAL STUDY; MALE; MICROVASCULATURE; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN TARGETING; SIGNAL TRANSDUCTION;

ADULT; AGED; AGED, 80 AND OVER; ASTROCYTOMA; BRAIN NEOPLASMS; COHORT STUDIES; FEMALE; HUMANS; IMMUNOTHERAPY; INTERLEUKIN-6; INTERLEUKIN-8; MALE; MICROVESSELS; MIDDLE AGED; NEOVASCULARIZATION, PATHOLOGIC; PROGNOSIS; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR; TUMOR MARKERS, BIOLOGICAL; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR NEOPLASMS;

EID: 79960894174     PISSN: 10434666     EISSN: 10960023     Source Type: Journal    
DOI: 10.1016/j.cyto.2011.05.012     Document Type: Article

References (47)

1. Louis D.N. Molecular pathology of malignant gliomas. Annu Rev Pathol 2006, 1:97-117.
2. Furnari F.B., Fenton T., Bachoo R.M., et al. Malignant astrocytic glioma: genetics, biology, and paths to treatment. Genes Dev 2007, 21:2683-2710.
3. Reijneveld J.C., Voest E., Taphoorn M.J. Angiogenesis in malignant primary and metastatic brain tumors. J Neurol 2000, 247:597-608.
4. Korkolopoulou P., Patsouris E., Konstantinidou A.E., et al. Hypoxia-inducible factor 1alpha/vascular endothelial growth factor axis in astrocytomas. Associations with microvessel morphometry, proliferation and prognosis. Neuropathol Appl Neurobiol 2004, 30:267-278.
5. Rao R.D., James C.D. Altered molecular pathways in gliomas: an overview of clinically relevant issues. Semin Oncol 2004, 31:595-604.
6. Brantley E.C., Benveniste E.N. Signal transducer and activator of transcription-3: a molecular hub for signaling pathways in gliomas. Mol Cancer Res 2008, 6:675-684.
7. Shuai K., Liu B. Regulation of JAK-STAT signaling in the immune system. Nat Rev Immunol 2003, 3:900-911.
8. Tchirkov A., Rolhion C., Bertrand S., et al. IL-6 gene amplification and expression in human glioblastomas. Br J Cancer 2001, 85:518-522.
9. Samaras V., Piperi C., Korkolopoulou P., et al. Application of the ELISPOT method for comparative analysis of interleukin (IL)-6 and IL-10 secretion in peripheral blood of patients with astroglial tumours. Mol Cell Biochem 2007, 304:343-351.
10. Zisakis A., Piperi C., Themistocleous M.S., et al. Comparative analysis of peripheral and localised cytokine secretion in glioblastoma patients. Cytokine 2007, 39:99-105.
11. Tchirkov A., Khalil T., Chautard E., et al. Interleukin-6 gene amplification and shortened survival in glioblastoma patients. Br J Cancer 2007, 96:474-476.
12. Samaras V., Piperi C., Levidou G., et al. Analysis of interleukin (IL)-8 expression in human astrocytomas: associations with IL-6, cyclooxygenase-2, vascular endothelial growth factor, and microvessel morphometry. Hum Immunol 2009, 70:391-397.
13. Salmaggi A., Eoli M., Frigerio S., et al. Intracavitary VEGF, bFGF, IL-8, IL-12 levels in primary and recurrent malignant glioma. J Neurooncol 2003, 62:297-303.
14. Hu D.E., Hori Y., Fan T.P. Interleukin-8 stimulates angiogenesis in rats. Inflammation 1993, 17:135-143.
15. Koch A.E., Polverini P.J., Kunkel S.L., et al. Interleukin-8 as a macrophage derived mediator of angiogenesis. Science 1992, 258:1798-1801.
16. Strieter R.M., Kunkel S.L., Elner V.M., et al. Interleukin-8. A corneal factor that induces neovascularization. Am J Pathol 1992, 141:1279-1284.
17. Loeffler S., Fayard B., Weis J., et al. Interleukin-6 induces transcriptional activation of vascular endothelial growth factor (VEGF) in astrocytes in vivo and regulates VEGF promoter activity in glioblastoma cells via direct interaction between STAT3 and Sp1. Int J Cancer 2005, 115:202-213.
18. Yu H., Jove R. The STATs of cancer - new molecular targets come of age. Nat Rev Cancer 2004, 4:97-105.
19. Korkolopoulou P., Patsouris E., Kavantzas N., et al. Prognostic implications of microvessel morphometry in diffuse astrocytic neoplasms. Neuropathol Appl Neurobiol 2002, 28:57-66.
20. Bowman T., Garcia R., Turkson J., et al. STATs in oncogenesis. Oncogene 2000, 19:2474-2488.
21. de la Iglesia N., Konopka G., Puram S.V., et al. Identification of a PTEN-regulated STAT3 brain tumor suppressor pathway. Genes Dev 2008, 22:449-462.
22. Weissenberger J., Loeffler S., Kappeler A., et al. IL-6 is required for glioma development in a mouse model. Oncogene 2004, 23:3308-3316.
23. Wang H., Zhang W., Huang H.J., et al. Analysis of the activation status of Akt, NFkappaB, and Stat3 in human diffuse gliomas. Lab Invest 2004, 84:941-951.
24. Mizoguchi M., Betensky R.A., Batchelor T.T., et al. Activation of STAT3, MAPK, and AKT in malignant astrocytic gliomas: correlation with EGFR status, tumor grade, and survival. J Neuropathol Exp Neurol 2006, 65:1181-1188.
25. Tu Y., Zhong Y., Fu J., et al. Activation of JAK/STAT signal pathway predicts poor prognosis of patients with gliomas. Med Oncol 2011, 28:15-23.
26. Birner P., Toumangelova-Uzeir K., Natchev S., Guentchev M. STAT3 tyrosine phosphorylation influences survival in glioblastoma. J Neurooncol 2010, 100:339-343.
27. de la Iglesia N., Konopka G., Lim K.L., et al. Deregulation of a STAT3-interleukin 8 signaling pathway promotes human glioblastoma cell proliferation and invasiveness. J Neurosci 2008, 28:5870-5878.
28. Louis D.N., Ohgaki H., Wiestler O.D., et al. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 2007, 114:97-109.
29. Hsieh F.Y., Lavori P.W. Sample-size calculations for the cox proportional hazards regression model with nonbinary covariates. Control Clin Trials 2000, 21:552-560.
30. Baggiolini M., Walz A., Kunkel S.L. Neutrophil-activating peptide-1/interleukin 8, a novel cytokine that activates neutrophils. J Clin Invest 1989, 84:1045-1049.
31. Tada M., Diserens A.C., Desbaillets I., et al. Analysis of cytokine receptor messenger RNA expression in human glioblastoma cells and normal astrocytes by reverse-transcription polymerase chain reaction. J Neurosurg 1994, 80:1063-1073.
32. Yamanaka R., Tanaka R., Saitoh T., et al. Cytokine gene expression on glioma cell lines and specimens. J Neurooncol 1994, 21:243-247.
33. Addison C.L., Daniel T.O., Burdick M.D., et al. The CXC chemokine receptor 2, CXCR2, is the putative receptor for ELR+ CXC chemokine-induced angiogenic activity. J Immunol 2000, 165:5269-5277.
34. Kim D.S., Kim J.H., Lee J.K., et al. Overexpression of CXC chemokine receptors is required for the superior glioma-tracking property of umbilical cord blood-derived mesenchymal stem cells. Stem Cells Dev 2009, 18:511-519.
35. Yao X.H., Ping Y.F., Chen J.H., et al. Production of angiogenic factors by human glioblastoma cells following activation of the G-protein coupled formylpeptide receptor FPR. J Neurooncol 2008, 86:47-53.
36. Korkolopoulou P., Perdiki M., Thymara I., et al. Expression of hypoxia-related tissue factors in astrocytic gliomas. A multivariate survival study with emphasis upon carbonic anhydrase IX. Hum Pathol 2007, 38:629-638.
37. Caldera V., Mellai M., Annovazzi L., et al. Stat3 expression and its correlation with proliferation and apoptosis/autophagy in gliomas. J Oncol 2008, 2008:219241.
38. Schaefer L.K., Menter D.G., Schaefer T.S. Activation of stat3 and stat1 DNA binding and transcriptional activity in human brain tumour cell lines by gp130 cytokines. Cell Signal 2000, 12:143-151.
39. Rahaman S.O., Harbor P.C., Chernova O., et al. Inhibition of constitutively active Stat3 suppresses proliferation and induces apoptosis in glioblastoma multiforme cells. Oncogene 2002, 21:8404-8413.
40. Tanaka T., Kanai H., Sekiguchi K., et al. Induction of VEGF gene transcription by IL-1 beta is mediated through stress-activated MAP kinases and Sp1 sites in cardiac myocytes. J Mol Cell Cardiol 2000, 32:1955-1967.
41. Treins C., Giorgetti-Peraldi S., Murdaca J., Semenza G.L., Van Obberghen E. Insulin stimulates hypoxia-inducible factor 1 through a phosphatidylinositol 3-kinase/target of rapamycin-dependent signaling pathway. J Biol Chem 2002, 277:27975-27981.
42. Brat D.J., Bellail A.C., Van Meir E.G. The role of interleukin-8 and its receptors in gliomagenesis and tumoural angiogenesis. Neurooncology 2005, 7:122-133.
43. Garkavtsev I., Kozin S.V., Chernova O., et al. The candidate tumour suppressor protein ING4 regulates brain tumour growth and angiogenesis. Nature 2004, 428:328-332.
44. Abou-Ghazal M., Yang D.S., Qiao W., et al. The incidence, correlation with tumor-infiltrating inflammation, and prognosis of phosphorylated STAT3 expression in human gliomas. Clin Cancer Res 2008, 14:8228-8235.
45. Bromberg J.F., Wrzeszczynska M.H., Devgan G., et al. Stat3 as an oncogene. Cell 1999, 98:295-303.
46. Rajan P., McKay R.D. Multiple routes to astrocytic differentiation in the CNS. J Neurosci 1998, 18:3620-3629.
47. Dolled-Filhart M., Camp R.L., Kowalski D.P., et al. Tissue microarray analysis of signal transducers and activators of transcription 3 (Stat3) and phospho-Stat3 (Tyr705) in node-negative breast cancer shows nuclear localization is associated with a better prognosis. Clin Cancer Res 2003, 9:594-600.